Although it is still too early to determine the safety and efficacy success rate of the many promising ongoing clinical trials targeting TGF-β function in combination with conventional therapy, one emerging aspect is its dependency on cancer subtype [71–73]. This evidence concerns the gene TGFB1 and cancer.